BYSI · Insider Trading
BeyondSpring Inc. Ordinary Shares
Every open-market purchase and sale reported by BYSI officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-07-06 | Jiangwen Majeti | Director | A | +100,000 deriv. | — |
| 2026-07-06 | Min Qiu | Chief Executive Officer | A | +100,000 deriv. | — |
| 2026-05-15 | Lan Huang | Chief Executive Officer | G | −260,582 | — |
| 2026-04-08 | Matthew Kirkby | Director | A | +23,902 deriv. | — |
| 2026-04-03 | Brendan Delaney | Director | A | +20,427 deriv. | — |
| 2026-04-03 | Patrick Fabbio | Director | A | +22,165 deriv. | — |
| 2026-04-03 | Lan Huang | Chief Executive Officer | A | +11,514 deriv. | — |
| 2026-04-03 | Jiangwen Majeti | Director | A | +21,730 deriv. | — |
| 2026-04-03 | Sihai Xu | Director | A | +18,689 deriv. | — |
| 2026-04-03 | Yingjuan June Lu | Chief Scientific Officer | A | +17,840 deriv. | — |
| 2025-10-20 | Decheng Capital China Life Sciences USD Fund II, L.P. | 10%+ Owner | Sell | −919,177 | −$1.59M |
| 2025-10-15 | Decheng Capital Global Healthcare GP, LLC | 10%+ Owner | Sell | −1,076,712 | −$1.81M |
| 2025-10-10 | Decheng Capital Global Healthcare Fund (Master), LP | 10%+ Owner | Sell | −97,132 | −$173.04K |
| 2025-10-07 | Decheng Capital China Life Sciences USD Fund II, L.P. | 10%+ Owner | Sell | −141,400 | −$251.75K |
| 2025-10-02 | Xiangmin Cui | 10%+ Owner | Sell | −53,655 | −$96.60K |
| 2025-09-29 | Decheng Capital China Life Sciences USD Fund II, L.P. | 10%+ Owner | Sell | −10,800 | −$18.27K |
| 2025-09-24 | Xiangmin Cui | 10%+ Owner | Sell | −70,632 | −$124.52K |
| 2025-09-19 | Xiangmin Cui | 10%+ Owner | Sell | −67,602 | −$119.97K |
| 2025-09-16 | Decheng Capital China Life Sciences USD Fund II, L.P. | 10%+ Owner | Sell | −24,660 | −$45.62K |
| 2025-09-11 | Decheng Capital China Life Sciences USD Fund III, L.P. | 10%+ Owner | Sell | −126,276 | −$245.20K |
| 2025-09-08 | Decheng Capital China Life Sciences USD Fund II, L.P. | 10%+ Owner | Sell | −53,994 | −$103.21K |
| 2025-09-03 | Decheng Capital China Life Sciences USD Fund II, L.P. | 10%+ Owner | Sell | −29,220 | −$52.05K |
| 2025-08-28 | Decheng Capital Global Healthcare GP, LLC | 10%+ Owner | Sell | −24,654 | −$44.15K |
| 2025-08-25 | Decheng Capital Management III (Cayman), LLC | 10%+ Owner | Sell | −34,260 | −$60.72K |
| 2025-08-20 | Xiangmin Cui | 10%+ Owner | Sell | −328,368 | −$654.95K |
| 2025-08-15 | Decheng Capital China Life Sciences USD Fund II, L.P. | 10%+ Owner | Sell | −29,400 | −$58.80K |
| 2025-08-11 | Decheng Capital Global Healthcare GP, LLC | 10%+ Owner | Sell | −2,366,616 | −$7.22M |
| 2025-04-23 | Yingjuan June Lu | Chief Scientific Officer | A | +18,981 deriv. | — |
| 2025-04-23 | Brendan Delaney | Director | A | +21,822 deriv. | — |
| 2025-04-23 | Matthew Kirkby | Director | A | +25,763 deriv. | — |
| 2025-04-23 | Lan Huang | Chief Executive Officer | A | +43,630 deriv. | — |
| 2025-04-23 | Jiangwen Majeti | Director | A | +23,300 deriv. | — |
| 2025-04-23 | Patrick Fabbio | Director | A | +23,793 deriv. | — |
| 2025-04-23 | Sihai Xu | Director | A | +19,852 deriv. | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| Decheng Capital Management III (Cayman), LLC | 10%+ Owner | 1,913,734 | $880.32K |
| Decheng Capital China Life Sciences USD Fund III, L.P. | 10%+ Owner | 1,874,710 | $862.37K |
| Xiangmin Cui | 10%+ Owner | 1,841,297 | $847.00K |
| Decheng Capital Global Healthcare GP, LLC | 10%+ Owner | 1,617,409 | $744.01K |
| Decheng Capital China Life Sciences USD Fund II, L.P. | 10%+ Owner | 1,564,406 | $719.63K |
| Decheng Capital Global Healthcare Fund (Master), LP | 10%+ Owner | 891,734 | $410.20K |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the BYSI quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.